Dystrophin MarketAs stated in our extensive report, providing insights on product and procedure the Global Market accounted for USD 1.31 Billion billion in 2021.
Deficiency in is the most common neuromuscular disease and affects all world populations equally. The cause of these genetic diseases is in all types of muscle (i.e., skeletal, cardiac, and smooth), loss of a single protein, , and in neurons. During the past 25 years, gene & protein identification has dozens of innovative experimental therapeutic approaches for deficiency have emerged. On the other hand, approaches to coax production out of the patient's own disabled gene have been more impressive. The rapid advancement in the development of small-molecule drugs for gene repairs overcome problems with target organ delivery, production, and immune response.
Recently, significant progress has been made with the first drug approval using a genetic approach and the application of pharmacological agents which slow the progression of the disease. Drug development for deficiency has mainly used two strategies such as the restoration of expression or the expression of the compensatory utrophin protein as an efficient surrogate, and the mitigation of secondary downstream pathological mechanisms. These are some of the treatments needed for treating the deficient population.
Asia Pacific is expected to grow at the fastest Compound Annual Growth Rate (CAGR) in coming years due to high demand for treating deficient people.Additionally, the region contains the world’s best Research and Development (R&D) facilities and hospitals for treating patients, hence it is expected to have a high demand for this treatment in this region. These are few reasons that is expected to grow the Market in the coming years.
Major players of the Market such as PTC Therapeutics, Sarepta Therapeutics, BioMarin Pharmaceutical Inc, Wave Life Sciences, Bristol-Myers Squibb and Catabasis, Pharmaceuticals among others..
Mar 27, 2024
